Guacetisal (Broncaspin). a new active principle, obtained from the esterification of acetylsalicylic acid with guaiacol, in the treatment of chronic bronchitis. Guacetisal was generally well tolerated. It has considerable therapeutic effectiveness and produced early, lasting reduction in temperature, heart frequency, dyspnoea, duration of expirium and in the intensity and number of coughing attacks. Guacetisal exerts its polyvalent activity to a proportionately higher extent in the bronchial districts more seriously involved in the inflammatory process, inducing an elective improvement in bronchial permeability, a reduction in total pulmonary resistances--with consequent tendency for ventilation-perfusion relations to normalise--as well as an improvement in gas exchanges and patient oxygenation[3]. Guacetisal was administered to a group of patients suffering from chronic asthmatic bronchitis. The drug in question was shown to possess a good fluidifying, expectorant and indirect anti-cough action, by means of an initial increase of the bronchial secretions and a subsequent progressive decrease of secretions towards the end of the treatment[4].
搜索
